Stockreport

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) releas [Read more]